▲ +43.59% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for Insmed in the last 3 months. The average price target is $53.43, with a high forecast of $60.00 and a low forecast of $44.00. The average price target represents a 43.59% upside from the last price of $37.21.
The current consensus among 7 polled investment analysts is to buy stock in Insmed. This Buy consensus rating has held steady for over two years.
Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.